Medicare is seeing a wave of updates in 2026 — and while the goal is to make prescription drugs more affordable overall, the reality is more nuanced. Some beneficiaries will pay less than before, while others may notice higher monthly premiums. One change that's getting a lot of attention is a $100 increase to the Part D out-of-pocket cap.
Here's what you need to know.
How the Part D Cap Has Changed
In 2025, Medicare Part D set a landmark out-of-pocket cap of $2,000 for covered prescription drugs. Once you hit that ceiling, you owed nothing more for covered medications for the rest of the calendar year.
Starting in 2026, that cap increases to $2,100. It applies to Medicare-covered prescriptions, certain vaccines, and qualifying medical devices.
Why Is the Cap $100 Higher?
The short answer is inflation. The cap was never designed to be a permanent fixed number — it was always intended to adjust over time in response to rising costs. A modest increase like this reflects that built-in flexibility.
That said, the bigger picture here is actually encouraging. Thanks to the Inflation Reduction Act (IRA), passed under the Biden administration, the old "donut hole" problem is gone. Before the IRA, Medicare Part D had a coverage gap that kicked in after you spent a certain amount, during which you were responsible for roughly 25% of drug costs. On top of that, there was a separate catastrophic coverage threshold — around $8,000 in 2024 — before costs dropped again.
The IRA eliminated that gap entirely and replaced it with the cleaner, single out-of-pocket cap structure. The 2026 figure of $2,100 is simply that cap adjusted for inflation.
Other Medicare Changes Coming in 2026
The cap isn't the only thing shifting this year. Here's a quick rundown of other updates:
- Part B premiums are rising. Monthly premiums for Medicare Part B were $185 in 2025. In 2026, they increase to $202.90 per month — the third consecutive year premiums have outpaced Social Security's cost-of-living adjustment. This spike reflects both higher care costs and increased utilization of medical services.
- Part A premiums are also up for those who don't qualify based on work history. Beneficiaries with 30 to 39 quarters of Medicare-covered employment will pay $311 per month, while those with fewer quarters may see premiums reach $565 per month.
- Medicare-negotiated drug prices take effect. This is a significant milestone. For the first time, Medicare's negotiated prices on a select group of drugs will be available to beneficiaries. Discounts range from 38% to 79% off 2023 list prices, which could mean real savings for people who rely on those specific medications.
- The insulin cap remains at $35. For people managing diabetes, the monthly cap on insulin costs stays at $35 per month's supply, regardless of whether you've met your deductible.
How Many Drugs Has Medicare Negotiated Prices For?
The first round of negotiations covered 10 drugs, with those lower prices going into effect in 2026. Medicare is actively working on a second round of negotiations, prioritizing medications that large numbers of beneficiaries depend on and that carry high out-of-pocket costs. The list is expected to grow meaningfully in the years ahead.
What Is the Inflation Reduction Act?
The Inflation Reduction Act is sweeping legislation that addressed several national priorities at once — energy, climate, and healthcare costs among them. For Medicare beneficiaries specifically, the law's most impactful provisions center on capping out-of-pocket drug spending, allowing Medicare to negotiate prices directly with manufacturers, and capping insulin costs. It represents one of the most significant changes to Medicare's prescription drug benefit since Part D launched in 2006.
Why Are Drug Prices Still So High?
Even with these reforms, many Americans — particularly those who are uninsured or underinsured — still face steep medication costs. Several structural issues keep prices elevated:
- The U.S. lacks a centralized drug price negotiation system for the broader market (outside of Medicare's new but limited authority).
- Pharmacy Benefit Managers (PBMs) act as intermediaries between insurers and manufacturers, and their role can add layers of cost rather than reduce them.
- Aggressive patent strategies by large manufacturers make it difficult for generic competitors to enter the market, keeping brand-name prices high for longer.
For people who fall outside Medicare or who can't afford their medications even with insurance, a prescription assistance program can be a lifeline.
Help Paying for Prescriptions Is Available
If you're uninsured, underinsured, or simply struggling with the cost of brand-name drugs, you don't have to navigate this alone. ClariMeds is a full-service patient assistance program that researches, qualifies, and manages enrollment in every available source of brand name drug financial assistance — including manufacturer assistance programs that provide free brand name medication to eligible patients.
Whether you need prescription help uninsured or you're looking for help paying for prescriptions that your current coverage doesn't fully cover, ClariMeds handles the paperwork and follow-up so you can focus on your health.
Ready to find out what you qualify for? Start your application here and a ClariMeds representative will be in touch within 24 hours to walk you through your options.